Today: 18 November 2025
Subscribe
Browse Category

Mergers & Acquisitions News 10 November 2025 - 12 November 2025

Salarius Pharmaceuticals (SLRX) Stock Jumps as $7M Offering Prices; Closing Expected November 12, 2025 Amid Decoy Therapeutics Merger

Salarius Pharmaceuticals (SLRX) Stock Jumps as $7M Offering Prices; Closing Expected November 12, 2025 Amid Decoy Therapeutics Merger

Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) is back in the headlines today after pricing a $7 million underwritten public offering tied to its pending business combination with Decoy Therapeutics. The company said the deal is expected to close “on or about November 12, 2025,” pending customary conditions, including consummation of the Decoy transaction. PR Newswire Key takeaways What happened today (Nov. 12, 2025) Salarius confirmed the pricing of its offering for gross proceeds of ~$7 million before fees. The package includes: The company notes the registration statement on Form S‑1 (File No. 333‑284368) became effective on Nov. 10, 2025, and the
12 November 2025
 ·  ·  ·  · 
Coinbase (COIN) Stock Crashes in Crypto Sell-Off – Can It Bounce Back?

Coinbase Walks Away From $2 Billion BVNK Deal as UK Weighs Strict Stablecoin Caps

Exclusive talks end without a deal, Fortune reports, while the Bank of England’s proposed holding limits draw industry fire and cloud the outlook for sterling stablecoins. Decrypt+1 Published: November 12, 2025 Key Points What Happened Coinbase has scrapped plans to acquire London-based stablecoin infrastructure firm BVNK after entering exclusive talks in October. The deal, pegged at about $2 billion, would have marked one of the sector’s larger transactions this year. A Coinbase spokesperson confirmed the breakup was mutual but did not provide a reason. Decrypt Fortune first reported the talks had collapsed; Coinbase had been seen as the front-runner after
12 November 2025
 ·  ·  ·  ·  · 
Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer (PFE) Today — Nov. 11, 2025: $10B Metsera Deal Nears Vote, Oncology Game Plan Expands, Shares Rise

Updated Nov. 11, 2025 Key takeaways Where the Metsera deal stands today Pfizer has agreed to acquire Metsera on final terms worth up to $10 billion, paying $65.60 in cash per share plus up to $20.65 per share in CVRs (maximum $86.25 per share). The structure, which Metsera’s board deemed superior on value and certainty of closing, is expected to go to a shareholder vote on Nov. 13 before closing. Reuters+1 While Novo Nordisk pushed the bidding to similar headline value, meticulous antitrust calculus tipped the field. Reuters Breakingviews reports that FTC outreach helped steer Metsera toward Pfizer; coupled with
11 November 2025
 ·  ·  ·  ·  ·  ·  · 
Paramount Skydance (NASDAQ: PSKY) Jumps on First Post‑Merger Earnings: $1.5B Content Push, $3B Cost Cuts, Paramount+ Price Hike — 11/11/2025

Paramount Skydance (NASDAQ: PSKY) Jumps on First Post‑Merger Earnings: $1.5B Content Push, $3B Cost Cuts, Paramount+ Price Hike — 11/11/2025

Paramount Skydance Corporation reported its first results since the Skydance–Paramount merger and the stock rallied after management laid out a bigger streaming-and-studios investment plan and raised its cost‑savings target. Shares were up ~5.5% today as CEO David Ellison emphasized a tech‑forward overhaul, a fatter content slate, and a sharper path to profitability. Reuters Quick take (today) What happened on November 11, 2025 Stock reaction & strategy. Investors bid PSKY higher after management raised its savings target to $3B, laid out >$1.5B in incremental 2026 programming investments, and reiterated a push to unify streaming platforms and ramp to ~15 theatrical releases
11 November 2025
 ·  ·  ·  ·  · 
Kaltura (KLTR) soars as Q3 beats, $27M eSelf.ai deal lands, and 14.4M-share buyback headlines — Nov. 11, 2025

Kaltura (KLTR) soars as Q3 beats, $27M eSelf.ai deal lands, and 14.4M-share buyback headlines — Nov. 11, 2025

What’s new today (Nov. 11, 2025) Shares surge after Q3 + AI deal headlines. KLTR is one of today’s bigger software movers. Benzinga’s pre‑market screen flagged KLTR up ~26.5% to $1.86 before the bell following last night’s results and acquisition news; live prices show the rally continuing after the open. Benzinga Local tech press amplifies the acquisition. Israeli outlet CTech detailed the $27M structure (including 4.69M Kaltura shares vesting over three years—about 3% of pre‑deal share base) and reiterated that closing is targeted for Q4 2025, pending approvals. TechCrunch highlighted co‑founder Dr. Alan Bekker’s prior sale of Voca.ai to Snap
11 November 2025
 ·  ·  ·  ·  · 
C3.ai (AI) shares edge higher as company explores sale — everything new on November 11, 2025

C3.ai (AI) shares edge higher as company explores sale — everything new on November 11, 2025

C3.ai, Inc. (NYSE: AI) is in the spotlight today after a late‑Monday Reuters exclusive said the enterprise‑AI software maker is exploring a potential sale as part of a broader strategic review following its recent leadership transition. Additional outlets echoed the report overnight in Asia and Europe, and traders are watching for follow‑on headlines ahead of the company’s next earnings date in early December. reuters.com+2thestar.com.my+2 The latest (Nov 11, 2025) Why this development matters What industry watchers are saying today Key dates and what to watch next Background: the road to today Quick FAQ (today’s essentials) Is C3.ai being sold?Not necessarily.
11 November 2025
 ·  ·  ·  ·  · 
Shiseido cuts 2025 outlook to ¥52bn net loss, books ¥46.8bn Americas impairment and launches 200‑person voluntary exit

Shiseido cuts 2025 outlook to ¥52bn net loss, books ¥46.8bn Americas impairment and launches 200‑person voluntary exit

Tokyo — November 10, 2025 Japan’s Shiseido Co. (TSE: 4911) slashed its full‑year guidance and flagged deeper restructuring, warning it now expects a ¥52 billion net loss for the year to December 31, 2025 (IFRS), versus a previous forecast for a ¥6 billion profit. The cosmetics group cited a goodwill impairment in the Americas and softer demand as it also unveiled a new medium‑term strategy through 2030. Shiseido Corporation+1 What Shiseido announced today Japanese media also highlighted the scale of the forecast swing and the impairment behind it. Kabutan+1 Restructuring: 200 voluntary retirements, after earlier headcount cuts Shiseido will offer
10 November 2025
 ·  ·  ·  · 
Axia Energia debuts AXIA3; court declares Oi bankrupt; Kepler Weber gets R$11 offer — Brazil market wrap (Nov 10)

Axia Energia debuts AXIA3; court declares Oi bankrupt; Kepler Weber gets R$11 offer — Brazil market wrap (Nov 10)

São Paulo — November 10, 2025. Key points Axia Energia: new tickers on B3 and NYSE Axia Energia—Eletrobras’ new name—debuted its tickers on B3 this Monday: AXIA3 (common), AXIA5 (preferred A) and AXIA6 (preferred B). On the NYSE, the company’s ADRs now trade as AXIA (common) and AXIA PR (preferred), replacing EBR and EBR.B. Axia marked the change with a bell‑ringing ceremony at B3 around 9 a.m. (Brasília). At 10:45 a.m., AXIA3 rose 1.84% to R$59.76 while AXIA6 advanced 1.57% to R$62.92. InfoMoney B3’s own investor portal Bora Investir confirms the new codes and trading name (“AXIA ENERGIA”). A Citibank
10 November 2025
 ·  ·  ·  · 
Metsera (MTSR) Sinks as Pfizer Seals Revised $10B Buyout; 8‑K Spells Out $65.60 Cash + Up to $20.65 CVR — Nov. 10, 2025

Metsera (MTSR) Sinks as Pfizer Seals Revised $10B Buyout; 8‑K Spells Out $65.60 Cash + Up to $20.65 CVR — Nov. 10, 2025

Shares of Metsera, Inc. (NASDAQ: MTSR) slumped on Monday after the obesity‑drug developer said it will proceed with a sweetened takeover by Pfizer that ends a high‑stakes bidding war with Novo Nordisk. Metsera accepted Pfizer’s revised offer late Friday; Novo dropped out over the weekend. In early U.S. trading today, MTSR fell ~15% as investors recalibrated expectations around the final deal structure. Key takeaways (Nov. 10) What changed today The revised terms, line by line (from today’s 8‑K) Metsera’s Form 8‑K filed this morning lays out material changes versus the September agreement: Why Novo bowed out — and the FTC’s
10 November 2025
 ·  ·  ·  ·  ·  ·  · 
Movano (NASDAQ: MOVE) Soars on All‑Stock Merger With Corvex to Create Secure AI‑Infrastructure Pure Play — Nov. 10, 2025

Movano (NASDAQ: MOVE) Soars on All‑Stock Merger With Corvex to Create Secure AI‑Infrastructure Pure Play — Nov. 10, 2025

What Happened Movano Inc. (NASDAQ: MOVE) and Corvex, Inc., a GPU‑accelerated AI cloud company, signed a definitive all‑stock merger agreement. The combined business will focus squarely on secure, high‑performance AI infrastructure—including GPU clusters for training/inference, confidential computing, and inference‑as‑a‑service—repositioning Movano away from consumer health wearables. Upon closing, “Movano Inc.” will be renamed “Corvex, Inc.” and move its headquarters to Arlington, Virginia. PR Newswire The boards of both companies have unanimously approved the transaction, which is targeted to close in Q1 2026, subject to customary approvals, Nasdaq listing conditions for the new shares, and the effectiveness of an S‑4 registration statement.
10 November 2025
 ·  ·  ·  ·  · 
Ondas Holdings (ONDS) names ex‑Rafael chief Yoav Har‑Even to OAS advisory board as Sentrycs acquisition advances — Nov. 10, 2025

Ondas Holdings (ONDS) names ex‑Rafael chief Yoav Har‑Even to OAS advisory board as Sentrycs acquisition advances — Nov. 10, 2025

Ondas Holdings Inc. (NASDAQ: ONDS) announced that Maj. Gen. (Ret.) Yoav Har‑Even, former President & CEO of Rafael Advanced Defense Systems, has joined the advisory board of Ondas Autonomous Systems (OAS), the company’s defense and security robotics unit. The move adds a veteran of multi‑domain operations and large defense programs to OAS at a time when Ondas is expanding its counter‑UAS and autonomous platforms portfolio. Ondas Holdings Inc. What happened today Stock snapshot As of early afternoon (14:11 UTC) on Monday, ONDS traded around $5.81, up ~10.5% on the day. Why this matters The Har‑Even appointment signals Ondas’ intent to
10 November 2025
 ·  ·  ·  ·  · 
Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Novo Nordisk and Pfizer Stocks Today (Nov. 10, 2025): Pfizer Clinches $10B Metsera Deal as Novo Rises on Exit and India Brand Move

Published: November 10, 2025 Summary: On Monday, Pfizer said it will acquire obesity‑drug developer Metsera in a deal worth up to $10 billion, while Novo Nordisk shares climbed after bowing out of the bidding war. Governance drama around Novo’s board intensified as Norway’s $1.5 trillion sovereign wealth fund said it would abstain from key votes this week. Separately, Novo struck a distribution pact in India to sell a new branded version of its semaglutide weight‑loss shot. Reuters+3Reuters+3Reuters+3 Key takeaways How NVO and PFE are trading today Pfizer seals Metsera deal: what’s in it and why it matters Pfizer’s agreement to
10 November 2025
 ·  ·  ·  ·  ·  · 
1 2 3 4 5 … 12
Go toTop